<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-8-75</article-id><article-id pub-id-type="pmid">18070336</article-id><article-id pub-id-type="doi">10.1186/1471-2350-8-75</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>CD209 </italic>in inflammatory bowel disease: a case-control study in the Spanish population</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>Concepci&#x000f3;n</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>conchita.npardo@gmail.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Oliver</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>javi_om@ipb.csic.es</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Mendoza</surname><given-names>Juan Luis</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jmendoza@meditex.es</email></contrib><contrib id="A4" contrib-type="author"><name><surname>G&#x000f3;mez-Garc&#x000ed;a</surname><given-names>Mar&#x000ed;a</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>mmrosarioes@yahoo.es</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Taxonera</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>ctaxo@inicia.es</email></contrib><contrib id="A6" contrib-type="author"><name><surname>G&#x000f3;mez</surname><given-names>Luis M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lgomez@cib.org.co</email></contrib><contrib id="A7" contrib-type="author"><name><surname>L&#x000f3;pez-Nevot</surname><given-names>Miguel A</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>nevot@juntadeandalucia.es</email></contrib><contrib id="A8" contrib-type="author"><name><surname>de la Concha</surname><given-names>Emilio G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>egomezdela.hcsc@salud.madrid.org</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Urcelay</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>eurcelay.hcsc@salud.madrid.org</email></contrib><contrib id="A10" corresp="yes" contrib-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>Alfonso</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>alfmdoncel@gmail.com</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Mart&#x000ed;n</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>martin@ipb.csic.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Servicio de Inmunolog&#x000ed;a Cl&#x000ed;nica, Hospital Cl&#x000ed;nico San Carlos, Madrid, Spain</aff><aff id="I2"><label>2</label>Instituto de Parasitolog&#x000ed;a y Biomedicina, CSIC, Granada, Spain</aff><aff id="I3"><label>3</label>Unidad de Enfermedad Inflamatoria Intestinal, Hospital Cl&#x000ed;nico San Carlos, Madrid, Spain</aff><aff id="I4"><label>4</label>Unidad de Enfermedad Inflamatoria Intestinal, Hospital Virgen de las Nieves, Granada, Spain</aff><aff id="I5"><label>5</label>Servicio de Inmunolog&#x000ed;a, Hospital Virgen de las Nieves, Granada, Spain</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>10</day><month>12</month><year>2007</year></pub-date><volume>8</volume><fpage>75</fpage><lpage>75</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/75"/><history><date date-type="received"><day>29</day><month>8</month><year>2007</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 N&#x000fa;&#x000f1;ez et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>N&#x000fa;&#x000f1;ez et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> N&#x000fa;&#x000f1;ez Concepci&#x000f3;n conchita.npardo@gmail.com </dc:author><dc:title> CD209 in inflammatory bowel disease: a case-control study in the Spanish population </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 8(1): 75-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2007)8:1&#x0003c;75&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The etiology of Ulcerative Colitis (UC) and Crohn's Disease (CD), considered together as Inflammatory Bowel Diseases (IBD), involves environmental and genetic factors. Although some genes are already known, the genetics underlying these diseases is complex and new candidates are continuously emerging. The <italic>CD209 </italic>gene is located in a region linked previously to IBD and a <italic>CD209 </italic>functional polymorphism (rs4804803) has been associated to other inflammatory conditions. Our aim was to study the potential involvement of this <italic>CD209 </italic>variant in IBD susceptibility.</p></sec><sec sec-type="methods"><title>Methods</title><p>We performed a case-control study with 515 CD patients, 497 UC patients and 731 healthy controls, all of them white Spaniards. Samples were typed for the <italic>CD209 </italic>single nucleotide polymorphism (SNP) rs4804803 by TaqMan technology. Frequency comparisons were performed using &#x003c7;<sup>2 </sup>tests.</p></sec><sec><title>Results</title><p>No association between <italic>CD209 </italic>and UC or CD was observed initially. However, stratification of UC patients by <italic>HLA-DR3 </italic>status, a strong protective allele, showed that carriage of the <italic>CD209</italic>_G allele could increase susceptibility in the subgroup of <italic>HLA-DR3</italic>-positive individuals (p = 0.03 OR = 1.77 95% CI 1.04&#x02013;3.02, <italic>vs. </italic>controls).</p></sec><sec><title>Conclusion</title><p>A functional variant in the <italic>CD209 </italic>gene, rs4804803, does not seem to be influencing Crohn's disease susceptibility. However, it could be involved in the etiology or pathology of Ulcerative Colitis in <italic>HLA-DR3</italic>-positive individuals but further studies are necessary.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Inflammatory bowel diseases comprise two distinct entities, Crohn's disease (CD) and Ulcerative Colitis (UC). Both forms are characterized by a chronic inflammation of the intestine, but several clinical and immunological profiles differ between them. IBD is a multifactorial disease: environmental factors seem to be involved in disease onset in genetically susceptible individuals. Common susceptibility genetic components exist for both diseases as evidenced apparently by the higher risk of developing UC in relatives of patients with CD or <italic>vice versa</italic>, but also specific genes seem to play an important role in the development or course of each disease. For CD, <italic>CARD15 </italic>mutations are the main susceptibility factors described in Caucasian populations [<xref ref-type="bibr" rid="B1">1</xref>]. On the other hand, <italic>HLA </italic>genes show stronger effects on UC in our population, specifically <italic>HLA-DR3 </italic>seems to have a protective role in the development of this disease [<xref ref-type="bibr" rid="B2">2</xref>]. However, a complex genetic contribution exists in both diseases and new etiological genes remain to be discovered.</p><p>DC-SIGN (dendritic cell-specific ICAM3-grabbing non-integrin), also named CD209, is a type II membrane protein member of the C-type lectin receptor superfamily. It is expressed by dendritic cells and is involved in pattern recognition and immunoregulation [<xref ref-type="bibr" rid="B3">3</xref>]. The gene coding for this protein, <italic>CD209</italic>, is located in the region 19p13, where a linkage peak to IBD resulted from a genomewide scan performed in Canadian families [<xref ref-type="bibr" rid="B4">4</xref>]. A promoter variant of this gene, rs4804803, affects its transcriptional activity <italic>in vitro </italic>and it has been associated to susceptibility or severity to some infections [<xref ref-type="bibr" rid="B5">5</xref>]. Recently, this polymorphism has been also associated to susceptibility to a subset of celiac disease patients, another inflammatory condition sharing with IBD alterations in mucosal immunoregulation [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>The aim of this study was to evaluate the relevance of the rs4804803 polymorphism in susceptibility to IBD.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Samples</title><p>A total of 515 Crohn's disease patients and 497 ulcerative colitis patients were collected from two Hospitals in Spain (Hospital Cl&#x000ed;nico San Carlos, Madrid; Hospital Virgen de las Nieves, Granada). All the patients were of Spanish white origin. Diagnosis of UC and CD was based on standard clinical, radiological, endoscopic, and histological criteria. Demographic and clinical characteristics of IBD patients are shown in Table <xref ref-type="table" rid="T1">1</xref>. A total of 731 healthy individuals were used as controls, all of them ethnically matched, they were blood donors and staff members. Written informed consent was obtained from all the participants in the study, which was approved by the Ethical Committee of Hospital Cl&#x000ed;nico San Carlos and the Ethical Committee of Hospital Virgen de las Nieves.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of IBD patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Ulcerative colitis</bold></td><td></td></tr></thead><tbody><tr><td align="left">Sex (% M)</td><td align="left">55</td></tr><tr><td align="left">Mean (SD) age at onset (y)</td><td align="left">35.1 (12.9)</td></tr><tr><td align="left">Mean (SD) disease duration (y)</td><td align="left">10.1 (7.1)</td></tr><tr><td align="left">Smoking habits (%)</td><td></td></tr><tr><td align="left">Never</td><td align="left">47.1</td></tr><tr><td align="left">Ex/current</td><td align="left">52.9</td></tr><tr><td align="left">Extraintestinal manifestations (%)</td><td align="left">44.4</td></tr><tr><td align="left">Disease location (%)</td><td></td></tr><tr><td align="left">&#x02003;Left sided (<underline>including proctitis</underline>)</td><td align="left">56.5</td></tr><tr><td align="left">&#x02003;Extensive colitis/Pancolitis</td><td align="left">43.5</td></tr><tr><td align="left">Surgery (%)</td><td align="left">13.8</td></tr><tr><td align="left">Immunosupression (%)</td><td align="left">24.4</td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left"><bold>Crohn's disease</bold></td><td></td></tr><tr><td colspan="2"><hr></hr></td></tr><tr><td align="left">Sex (% M)</td><td align="left">49.1</td></tr><tr><td align="left">Mean (SD) age at onset (y)</td><td align="left">28.3 (12.5)</td></tr><tr><td align="left">&#x02003;&#x0003c;40 (A1)</td><td align="left">81.2</td></tr><tr><td align="left">&#x02003;&#x0003e;40 (A2)</td><td align="left">18.8</td></tr><tr><td align="left">Mean (SD) disease duration (y)</td><td align="left">9.4 (6.3)</td></tr><tr><td align="left">Smoking habits (%)</td><td></td></tr><tr><td align="left">&#x02003;Never</td><td align="left">51.5</td></tr><tr><td align="left">&#x02003;Ex/current</td><td align="left">48.5</td></tr><tr><td align="left">Disease location</td><td></td></tr><tr><td align="left">&#x02003;Ileal (L1)</td><td align="left">43.2</td></tr><tr><td align="left">&#x02003;Colonic (L2)</td><td align="left">17.2</td></tr><tr><td align="left">&#x02003;Ileocolonic (L3)</td><td align="left">35.0</td></tr><tr><td align="left">&#x02003;Upper GI tract (L4)</td><td align="left">4.5</td></tr><tr><td align="left">Disease Behavior</td><td></td></tr><tr><td align="left">&#x02003;Inflammatory (B1)</td><td align="left">40.9</td></tr><tr><td align="left">&#x02003;Stricturing (B2)</td><td align="left">19.3</td></tr><tr><td align="left">&#x02003;Perforating (B3)</td><td align="left">39.8</td></tr></tbody></table><table-wrap-foot><p>Values are calculated only from those patients with available data. Vienna classification has been used to classify CD patients.</p></table-wrap-foot></table-wrap></sec><sec><title>Genotyping</title><p>One single nucleotide polymorphism (SNP), rs4804803, was analyzed by TaqMan technology as previously described [<xref ref-type="bibr" rid="B6">6</xref>]. The two SNPs studied in the <italic>CARD15 </italic>gene were analyzed using C__11717468_20 (R702W, rs2066844) and C__11717466_20 (G908R, rs2066845) assays on Demand from Applied Biosystems (Foster City, CA). The 1007fs deletion (rs2066847) in the same gene was studied by an Assay by Design, also from Applied Biosystems. <italic>HLA-DR </italic>typing had been previously performed in the UC and CD patients, respectively, as well as in controls, as described before [<xref ref-type="bibr" rid="B7">7</xref>].</p></sec><sec><title>Statistical Analysis</title><p>Allelic and genotypic frequencies were compared between groups by means of &#x003c7;<sup>2 </sup>tests. Statistical analyses were performed using the statistical package EpiInfo v5.00 (CDC, Atlanta, USA).</p></sec></sec><sec><title>Results</title><p>No significant differences were observed when genotypic or allelic frequencies of the <italic>CD209 </italic>polymorphism studied were compared between CD or UC patients and controls (Table <xref ref-type="table" rid="T2">2</xref>). However, the stratification of UC patients by <italic>HLA-DR3</italic>, a genetic factor protective for UC (p = 0.00002; OR = 0.48), showed association of the <italic>CD209 </italic>SNP with UC only in <italic>HLA-DR3</italic>-positive patients (Table <xref ref-type="table" rid="T3">3</xref>). When <italic>HLA-DR3</italic>-positive patients were compared with controls a similar association emerged (p = 0.03 OR = 1.77 95% CI 1.04&#x02013;3.02). Stratification of CD patients by the presence of <italic>CARD15 </italic>mutations did not show any significant result (data not shown). Similarly, no association was found after location was considered (left-sided vs. extensive colitis for UC, and ileal vs. colonic for CD).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Genotypic and allelic frequencies of <italic>CD209 </italic>rs4804803 in CD and UC patients and in controls</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><italic>CD209</italic></td><td align="left" colspan="2">Controls</td><td align="left" colspan="2">CD</td><td align="left" colspan="2">UC</td><td align="left">Controls <italic>vs</italic>. CD</td><td align="left">Controls <italic>vs</italic>. UC</td></tr></thead><tbody><tr><td></td><td align="left">n = 731</td><td align="left">%</td><td align="left">n = 515</td><td align="left">%</td><td align="left">n = 497</td><td align="left">%</td><td></td><td></td></tr><tr><td align="left">AA</td><td align="left">446</td><td align="left">0.61</td><td align="left">293</td><td align="left">0.57</td><td align="left">294</td><td align="left">0.59</td><td align="left">Overall, p = 0.27</td><td align="left">Overall, p = 0.54</td></tr><tr><td align="left">AG</td><td align="left">251</td><td align="left">0.34</td><td align="left">191</td><td align="left">0.37</td><td align="left">184</td><td align="left">0.37</td><td align="left">Carriers G, p = 0.14 OR = 1.19 (0.94&#x02013;1.50)</td><td align="left">Carriers G, p = 0.51 OR = 1.08 (0.85&#x02013;1.37)</td></tr><tr><td align="left">GG</td><td align="left">34</td><td align="left">0.05</td><td align="left">31</td><td align="left">0.06</td><td align="left">19</td><td align="left">0.04</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">A</td><td align="left">1143</td><td align="left">0.78</td><td align="left">777</td><td align="left">0.75</td><td align="left">772</td><td align="left">0.78</td><td align="left">G <italic>vs</italic>. A, p = 0.11 OR = 1.17 (0.96&#x02013;1.41)</td><td align="left">G <italic>vs</italic>. A, p = 0.76 OR = 1.03 (0.84&#x02013;1.26)</td></tr><tr><td align="left">G</td><td align="left">319</td><td align="left">0.22</td><td align="left">253</td><td align="left">0.25</td><td align="left">222</td><td align="left">0.22</td><td></td><td></td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Genotypic and allelic frequencies in Ulcerative Colitis patients stratified by <italic>HLA-DR3 </italic>status</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><italic>CD209</italic></td><td align="left"><italic>DR3</italic>-positive</td><td></td><td align="left"><italic>DR3</italic>-negative</td><td></td><td align="left"><italic>DR3</italic>-positive vs. <italic>DR3</italic>-negative</td></tr></thead><tbody><tr><td></td><td align="left">n = 66</td><td align="left">%</td><td align="left">n = 431</td><td align="left">%</td><td></td></tr><tr><td align="left">AA</td><td align="left">31</td><td align="left">0.47</td><td align="left">261</td><td align="left">0.61</td><td align="left">Overall, p = 0.08</td></tr><tr><td align="left">AG</td><td align="left">33</td><td align="left">0.50</td><td align="left">153</td><td align="left">0.35</td><td align="left">Carriers G, p = 0.04 OR = 1.73 (1.00&#x02013;3.01)</td></tr><tr><td align="left">GG</td><td align="left">2</td><td align="left">0.03</td><td align="left">17</td><td align="left">0.04</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">A</td><td align="left">95</td><td align="left">0.72</td><td align="left">675</td><td align="left">0.78</td><td align="left">G <italic>vs</italic>. A, p = 0.10 OR = 1.41 (0.91&#x02013;2.16)</td></tr><tr><td align="left">G</td><td align="left">37</td><td align="left">0.28</td><td align="left">187</td><td align="left">0.22</td><td></td></tr></tbody></table></table-wrap></sec><sec><title>Discussion</title><p>We have studied the influence of the functional polymorphism rs4804803 of <italic>CD209 </italic>in susceptibility to UC and CD in the Spanish population. This gene seems to be increasing UC susceptibility in a subgroup of patients, those carrying <italic>HLA-DR3</italic>. It is known that <italic>HLA-DR3 </italic>is a strong protective factor for the development of the disease (<italic>HLA-DR3 </italic>allele: 7% in UC patients <italic>vs</italic>. 13% in controls, p = 5.7*10<sup>-7 </sup>OR = 0.48 95% CI 0.36&#x02013;0.63). Thus, <italic>HLA-DR3</italic>-positive patients, <italic>i.e.</italic>, those patients with minimal HLA genetic contribution to susceptibility, might present some additional susceptibility factors when compared with <italic>HLA-DR3</italic>-negative patients. Albeit the association described here barely reaches statistical significance, it seems rather interesting because a most similar effect of this gene has been recently described in other intestinal inflammatory pathology, celiac disease [<xref ref-type="bibr" rid="B6">6</xref>]. The <italic>CD209 </italic>gene was found to be increasing celiac disease susceptibility only in <italic>HLA-DQ2</italic>-negative patients, <italic>i.e.</italic>, those lacking the main genetic susceptibility factor described to celiac disease. Allele rs4804803_G seems to be involved in susceptibility to both diseases. A similar hypothesis to the one proposed in relation to celiac disease could be working in this case; the lower transcriptional activity consequence of the rs4804803_G allele would imply minor surveillance capacity of dendritic cells and probably increased persistence of pathogens in the gut. In these conditions, a chronic inflammation could ensue. A role of pathogens in initiation or maintaining of the inflammatory process in IBD has been repeatedly proposed [<xref ref-type="bibr" rid="B8">8</xref>]; CD209 could be one of the receptors involved in the recognition of some of those pathogens. This role of <italic>CD209 </italic>in UC is compatible with the stronger impact of environmental factors described in UC compared to CD [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>However, the weak statistical significance obtained makes necessary further analyses to confirm the influence of the <italic>CD209 </italic>rs4804803_G allele in susceptibility to <italic>HLA-DR3 </italic>positive UC patients in other populations and specially to investigate the involvement of this functional polymorphism in other chronic inflammatory conditions, mainly in those in whose origin pathogens could be involved. As a matter of fact, it is known that several common genes are underlying different autoimmune diseases [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>Ulcerative colitis has been often proposed to be a heterogeneous group of diseases included together because of their clinical similarities [<xref ref-type="bibr" rid="B11">11</xref>]. Therefore, it is not surprising to find particular genes affecting only a previously well-defined genetic subset of patients. This kind of findings could be rewarding from a therapeutic perspective since patients potentially responding to a specific treatment could be previously selected.</p></sec><sec><title>Conclusion</title><p>We reported a new susceptibility factor affecting to an ulcerative colitis subgroup of patients, those carrying <italic>HLA-DR3</italic>. Because CD209 is involved in pathogen recognition and the rs4804803_G <italic>CD209 </italic>allele results in lower transcriptional activity, the presence of this allele might generate an increased persistence of pathogens in the gut and consequently a chronic inflammation.</p></sec><sec><title>Abbreviations</title><p>caspase recruitment domain 15 (CARD15); Crohn's Disease (CD); Human leukocyte antigen (HLA); Inflammatory Bowel Diseases (IBD); Single nucleotide polymorphism (SNP); Ulcerative Colitis (UC).</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>CN and JA carried out the genotyping of the samples, participated in the statistical analysis and drafted the manuscript. LMG participated in the statistical analysis and revised the manuscript. JLM, MGG, CT and MALP made the diagnosis, collaborated in collection of samples and revised critically the manuscript. EGC coordinated the study and critically revised the manuscript. EU, AM and JM conceived the study, participated in the statistical analysis and completed the writing of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/75/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by grants SAF2003-08522 and SAF2006-00398. Concepci&#x000f3;n N&#x000fa;&#x000f1;ez and Alfonso Mart&#x000ed;nez have a FIS contract (CA06/0163 and CP04/00175, respectively) and Elena Urcelay works for the "Fundaci&#x000f3;n para la Investigaci&#x000f3;n Biom&#x000e9;dica-Hospital Cl&#x000ed;nico San Carlos".</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaya</surname><given-names>DR</given-names></name><name><surname>Russell</surname><given-names>RK</given-names></name><name><surname>Nimmo</surname><given-names>ER</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name></person-group><article-title>New genes in inflammatory bowel disease: lessons for complex diseases?</article-title><source>Lancet</source><year>2006</year><volume>367</volume><fpage>1271</fpage><lpage>1284</lpage><pub-id pub-id-type="pmid">16631883</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(06)68345-1</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de la Concha</surname><given-names>EG</given-names></name><name><surname>Fernandez-Arquero</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Vigil</surname><given-names>P</given-names></name><name><surname>Vidal</surname><given-names>F</given-names></name><name><surname>Lopez-Nava</surname><given-names>G</given-names></name><name><surname>Diaz-Rubio</surname><given-names>M</given-names></name><name><surname>Garcia-Paredes</surname><given-names>J</given-names></name></person-group><article-title>Amino acid polymorphism at residue 71 in HLA-DR beta chain plays a critical role in susceptibility to ulcerative colitis</article-title><source>Dig Dis Sci</source><year>1999</year><volume>44</volume><fpage>2324</fpage><lpage>2329</lpage><pub-id pub-id-type="pmid">10573382</pub-id><pub-id pub-id-type="doi">10.1023/A:1026629409481</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>DC-SIGN and immunoregulation</article-title><source>Cell Mol Immunol</source><year>2006</year><volume>3</volume><fpage>279</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">16978536</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Steinhart</surname><given-names>AH</given-names></name><name><surname>McLeod</surname><given-names>RS</given-names></name><name><surname>Griffiths</surname><given-names>AM</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Brettin</surname><given-names>TS</given-names></name><name><surname>Stone</surname><given-names>V</given-names></name><name><surname>Bull</surname><given-names>SB</given-names></name><name><surname>Bitton</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>CN</given-names></name><name><surname>Greenberg</surname><given-names>GR</given-names></name><name><surname>Cohen</surname><given-names>Z</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Siminovitch</surname><given-names>KA</given-names></name></person-group><article-title>Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci</article-title><source>Am J Hum Genet</source><year>2000</year><volume>66</volume><fpage>1863</fpage><lpage>1870</lpage><pub-id pub-id-type="pmid">10777714</pub-id><pub-id pub-id-type="doi">10.1086/302913</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakuntabhai</surname><given-names>A</given-names></name><name><surname>Turbpaiboon</surname><given-names>C</given-names></name><name><surname>Casademont</surname><given-names>I</given-names></name><name><surname>Chuansumrit</surname><given-names>A</given-names></name><name><surname>Lowhnoo</surname><given-names>T</given-names></name><name><surname>Kajaste-Rudnitski</surname><given-names>A</given-names></name><name><surname>Kalayanarooj</surname><given-names>SM</given-names></name><name><surname>Tangnararatchakit</surname><given-names>K</given-names></name><name><surname>Tangthawornchaikul</surname><given-names>N</given-names></name><name><surname>Vasanawathana</surname><given-names>S</given-names></name><name><surname>Chaiyaratana</surname><given-names>W</given-names></name><name><surname>Yenchitsomanus</surname><given-names>PT</given-names></name><name><surname>Suriyaphol</surname><given-names>P</given-names></name><name><surname>Avirutnan</surname><given-names>P</given-names></name><name><surname>Chokephaibulkit</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Yoksan</surname><given-names>S</given-names></name><name><surname>Jacob</surname><given-names>Y</given-names></name><name><surname>Lathrop</surname><given-names>GM</given-names></name><name><surname>Malasit</surname><given-names>P</given-names></name><name><surname>Despres</surname><given-names>P</given-names></name><name><surname>Julier</surname><given-names>C</given-names></name></person-group><article-title>A variant in the CD209 promoter is associated with severity of dengue disease</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>507</fpage><lpage>13. Epub 2005 Apr 17.</lpage><pub-id pub-id-type="pmid">15838506</pub-id><pub-id pub-id-type="doi">10.1038/ng1550</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nunez</surname><given-names>C</given-names></name><name><surname>Rueda</surname><given-names>B</given-names></name><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Maluenda</surname><given-names>C</given-names></name><name><surname>Polanco</surname><given-names>I</given-names></name><name><surname>Lopez-Nevot</surname><given-names>MA</given-names></name><name><surname>Ortega</surname><given-names>E</given-names></name><name><surname>Sierra</surname><given-names>E</given-names></name><name><surname>Gomez de la Concha</surname><given-names>E</given-names></name><name><surname>Urcelay</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name></person-group><article-title>A functional variant in the CD209 promoter is associated with DQ2-negative celiac disease in the Spanish population</article-title><source>World J Gastroenterol</source><year>2006</year><volume>12</volume><fpage>4397</fpage><lpage>4400</lpage><pub-id pub-id-type="pmid">16865785</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de la Concha</surname><given-names>EG</given-names></name><name><surname>Fernandez-Arquero</surname><given-names>M</given-names></name><name><surname>Lopez-Nava</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Allcock</surname><given-names>RJ</given-names></name><name><surname>Conejero</surname><given-names>L</given-names></name><name><surname>Paredes</surname><given-names>JG</given-names></name><name><surname>Diaz-Rubio</surname><given-names>M</given-names></name></person-group><article-title>Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL</article-title><source>Gastroenterology</source><year>2000</year><volume>119</volume><fpage>1491</fpage><lpage>1495</lpage><pub-id pub-id-type="pmid">11113070</pub-id><pub-id pub-id-type="doi">10.1053/gast.2000.20258</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>BJ</given-names></name><name><surname>Rhodes</surname><given-names>JM</given-names></name></person-group><article-title>Bacteria in the pathogenesis of inflammatory bowel disease</article-title><source>Curr Opin Infect Dis</source><year>2006</year><volume>19</volume><fpage>475</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">16940872</pub-id><pub-id pub-id-type="doi">10.1097/01.qco.0000244054.69253.f3</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>RK</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name></person-group><article-title>IBD: a family affair</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2004</year><volume>18</volume><fpage>525</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">15157825</pub-id><pub-id pub-id-type="doi">10.1016/j.bpg.2003.12.006</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>SH</given-names></name><name><surname>Merriman</surname><given-names>TR</given-names></name></person-group><article-title>Genetic progress towards the molecular basis of autoimmunity</article-title><source>Trends Mol Med</source><year>2006</year><volume>12</volume><fpage>90</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">16412690</pub-id><pub-id pub-id-type="doi">10.1016/j.molmed.2005.12.005</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Targan</surname><given-names>SR</given-names></name><name><surname>Karp</surname><given-names>LC</given-names></name></person-group><article-title>Defects in mucosal immunity leading to ulcerative colitis</article-title><source>Immunol Rev</source><year>2005</year><volume>206</volume><fpage>296</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">16048556</pub-id><pub-id pub-id-type="doi">10.1111/j.0105-2896.2005.00286.x</pub-id></citation></ref></ref-list></back></article> 